5TH International Congress on Technology - Engineering & Science - Kuala Lumpur - Malaysia (2018-02-01)

[bis(2,2’–bipyridine)(salphen)ruthenium(ii)] Complexes As Anticancer Agents

Among the several metal ions other than platinum that are currently being investigated for their anticancer activity, ruthenium occupies a prominent position. Research carried out in the past decade provide a significant number of ruthenium based drugs against cancer cell lines. Because of their different oxidation state, the fast ligand-exchange rate and the efficient binding to DNA and proteins ruthenium(II) complexes are attractive for biological systems as probes, imaging agents and their good cytotoxic activity. Further the binding ability of metal-salen and -salphen complexes (salen = ethylene diamine; phenylene diamine = salphen) with biomolecules depends on the nature of the metal. In the present study, we have synthesized several [bis(2,2’–bipyridine)(salphen)ruthenium(II)] complexes from cis-bis(2,2-bipyridyl)dichlororuthenium(II) dihydrate and substituted salphen ligands and characterized them by spectral techniques. These complexes are weakly luminescent in aqueous solution but luminescence is enhanced in the presence of protein HSA. The lympocytotoxicity of these complexes against the normal lymphocytes assessed by the lympocytotoxicity assay shows that Ru(II)–salphen complexes are non-toxic to normal cell lymphocytes isolated from human blood samples, revealing that they are selective in killing only the cancer cells which have excellent cytotoxic activity with potential applications for cell imaging. The cytotoxicity of these complexes against the MCF-7 cell lines and AGS gastric cell lines are assessed by the MTT assay.
Keywords: efv
GOMATHI SANKARESWARI VELUSAMY, RAJAGOPAL SEENIVASAN, RAMARAJ RAMASAMY